GlaxoSmithKline gets approval from China's National Drug Administration for listing

yesterday (July 16), GlaxoSmithKline (GSK) announced that Belista (belimumab, injection Bellevue) had been approved by theRegulatory Authority of China'sMedicines(http:// for listingThis time in China has been approved in combination with conventional treatment, suitable for active, autoantibody-positive SLE adult patients who are still active and autoantie-positive on the basis of conventional treatmentAt the end of April 2019, Benlysta intravenous preparations were approved by the U.SFDA(http://for use in children 5 years and older with SLE, becoming the onlydrug(http://specifically approved for the treatment of adult and child SLeAbout Benlysta
Benlysta is an all-human monoclonal antibody drug, intravenous administration, inhibits the proliferation and differentiation of B cells, induces autoactive B-cell apoptosis, thereby reducing the self-antibodies in the serum, to achieve the purpose of treating SLEBenlysta is the first B lymphocyte stimulator (Blythe abor, BLyS)-specific inhibitor that blocks the binding of soluble BLyS (a B-cell survival factor) to BLyS receptors on B cellsBenlysta does not bind directly to B cells, but by binding to BLyS, Benlysta inhibits the survival of B cells (including auto-reactive B cells) and reduces the differentiation of B cells into the plasma cells that make immunoglobulins 　　Benlysta reduces the number of abnormal B lymphocytes that worsen lupus patients, which cause the immune system to produce cells that mistakenly attack blood vessels and
other healthy (http:// tissues, causing lupus and other immune system diseases